Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
A bull market is here, but not every stock is benefiting. Some players remain in the doldrums. It's up to investors to decide whether those left behind are likely to remain there or make top buying opportunities today that could deliver great rewards down the road.
Wall Street is particularly enthusiastic about two beaten-down biotech stocks that soared in the earlier days of the pandemic. These two developed coronavirus vaccine candidates, and investors were betting they could eventually commercialize the products and win big. One reached commercialization but sales disappointed, while the other hasn't yet reached the vaccine finish line.
Read below to discover whether Wall Street's exuberance about these two struggling stocks was justified.
Source Fool.com
